SUMMARY The deleterious effects of corticosteroids (CS) on bone are well known, but probably differ depending on duration and dosage of CS therapy. Presently huge amounts of CS are given over a short period of time in different rheumatic conditions. Not much is known about the effect of this kind of CS treatment on bone metabolism. Twenty patients with persistently active rheumatoid arthritis were treated with 1 g methylprednisolone (MP) three times on alternate days over a five day period. Twenty four hours after the first MP pulse serum calcium was increased and the values of parathyroid hormone and 1,25-dihydroxyvitamin D tended to increase. After the second MP pulse, however, these values had returned to the starting values. The urinary calcium excretion increased during MP pulse therapy and returned to the initial value immediately after the pulse therapy. The hydroxyproline excretion tended to decrease during therapy and stayed decreased immediately afterwards, indicating a decrease in bone resorption. It is concluded that bone metabolism is not seriously affected during MP pulse therapy.
Rheumatoid arthritis (RA) is associated with a local and a generalised change in bone metabolism. The juxta-articular osteopenia, a hallmark of roentgenological changes, appears to be mediated by local inflammation. In addition, a more generalised involvement of the axial and peripheral skeleton may occur. This generalised involvement is probably related to loss of mobility' and often, subsequent lack of sunshine. When the disease progresses the use of concomitant corticosteroid (CS) therapy enhances the development of osteopenia, and perhaps this is the most important factor in clinically relevant osteopenia in RA.
Because of the deleterious side effects of CS many rheumatologists try to refrain from CS treatment. Nevertheless, steroids do ameliorate rheumatic inflammation and they are used quite often. During a recent conference on the role of steroids in the treatment of arthritis it was noted that 'preaching differed considerably from practice' and that as Accepted The patients were admitted to the hospital and they were advised to stay in bed during the first five to seven days. They received 1 g MP infusion over 30 minutes, three times on alternate days over a five day period. Urine was collected during 24 h a day, starting two days before the MP pulse therapy and continuing until three days after the last MP infusion. Fasting blood samples were drawn before the first pulse, 24 h after the first, 24 h after the second, and three days after the last MP pulse infusion. On the fourth or fifth day after the last infusion the patients were discharged from hospital. On the day of the first MP pulse they also started treatment with 50 mg azathioprine daily; this drug does not influence bone metabolism.
The following determinations were performed: The concentrations of urinary Ca, Cr, and OHProl were expressed in mmol/l and the following ratios were calculated: Ca/Cr and OHProl (x 1000)/ Cr. In our experience the normal values for these ratios are: Ca/Cr -0 30 and OHProl/Cr -20.5
The data obtained were analysed by means of a non-parametric test (Wilcoxon).
Results
In Table 1 the relevant data are summarised. In Figs 1 and 2 these data are further illustrated.
Serum Ca was significantly increased 24 h after the first MP pulse but returned to the baseline values 24 h after the second pulse and decreased further after the last pulse. There were no significant changes found in the concentrations of PTH, 25-OHD3, and 1a,25(OH2)D3. There was a tendency for PTH and la,25(OH2)D3 to increase after the first pulse, but 24 h after the second pulse these values returned to the starting values. It should be noted that the starting values showed a slightly raised PTH concentration (normal values <40 jtg/l). This has been noted before in RA. The concentrations of 25-OHD3 and 1a,25(OH2)D3 were in the (lower) normal range. The starting values of Ca/Cr and OHProl/Cr excretion in the urine were slightly above normal values.
In Fig. 2 the data for the urinary excretion of Ca and OHProl are shown in more detail. Firstly, the mean of the values of two 24 h periods before therapy are shown, then the data for the different days during the MP pulse therapy, and finally the data for the mean of three 24 h periods after the MP pulse therapy. During MP pulse therapy the Ca excretion rose and the OHProl excretion tended to decrease. On the day of the first MP pulse the Ca excretion was slightly decreased, followed by an increase, peaking on the day of the second MP pulse therapy. Later on Ca excretion decreased and reached normal values immediately after pulse therapy. The OHProl excretion, however, tended to stay decreased. It is clear from our limited data that the short term effects of high dose CS therapy differ from the known effects of long term CS therapy on bone metabolism. Perhaps the transient character may be caused by counter-regulatory effects, well known in the complicated processes of calcium homeostasis and bone metabolism. Further study and confirmation of our data are needed.
So far we have not noted any long term side effects such as osteonecrosis of the hip in our patients, but the follow up period is short.
In conclusion, bone resorption seems to decrease, but bone metabolism is not affected seriously and only transiently by MP pulse therapy. This study adds to the evidence that the effects of CS on bone differ with duration and dosage of the therapy.
